Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome.
Saved in:
| Title: | Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome. |
|---|---|
| Authors: | Mallett G; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Kamala O; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Pappworth IY; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Smith-Jackson K; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Gibson BG; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Asif M; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Denton H; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Cox C; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom., Walsh P; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Kavanagh D; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Marchbank KJ; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Apr 28; Vol. 17, pp. 1828298. Date of Electronic Publication: 2026 Apr 28 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1828298 |
